Objective Use of the frailty index to measure an accumulation of deficits has been proven a
valuable method for identifying elderly people at risk for increased vulnerability, disease …

Cardiovascular disease is the leading cause of death in patients with chronic kidney disease
(CKD). As CKD progresses, CKD-specific risk factors, such as disordered mineral …

Fibroblast growth factor (FGF) 23 is a phosphaturic hormone whose physiologic actions on
target tissues are mediated by FGF receptors (FGFR) and klotho, which functions as a co …

Cardiac remodeling occurs frequently in chronic kidney disease patients and affects quality
of life and survival. Current treatment options are highly inadequate. As kidney function …

Mineralocorticoid receptor (MR) activation is involved in propagating kidney injury,
inflammation, and fibrosis and in the progression of chronic kidney disease (CKD). Multiple …

Cardiac fibrosis plays an indispensable role in cardiac tissue homeostasis and repair after
myocardial infarction (MI). The cardiac fibroblast-to-myofibroblast differentiation and …

Abstract Fibroblast growth factor 23 (FGF23) is an important bone hormone that regulates
phosphate homeostasis in the kidney along with active vitamin D (1, 25 (OH) 2D3) and …

Patients with chronic kidney disease (CKD) are prone to developing cardiac hypertrophy
and fibrosis, which is associated with increased fibroblast growth factor 23 (FGF23) serum …

Fibroblast growth factor 23 (FGF 23) is mainly produced in the bone and, upon secretion,
forms a complex with a FGF receptor and coreceptor αKlotho. FGF 23 can exert several …

Fibroblast growth factor (FGF) 23 is a bone-derived phosphotropic hormone that regulates
phosphate and mineral homeostasis. Recent studies have provided evidence that a high …